Latest Wellnex Life (ASX:WNX) News

Wellnex Life has secured a significant opening order from global partner Haleon for its Liquid Paracetamol and Ibuprofen softgel products in the UAE, marking the fourth national market in Haleon's distribution network. This milestone supports Wellnex's revenue forecasts for 2025 and underscores its strategic focus on innovative healthcare products.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

Wellnex Life reported a strong 40.4% revenue increase to $23.6 million in FY25, alongside a 57% improvement in normalised EBITDA loss, signaling progress despite ongoing investment costs.

Wellnex Life Limited reported a strong 40% revenue increase in FY25 driven by its Pain Away brand, yet posted a wider loss due to one-off costs and finance expenses. The company’s balance sheet strengthened following a dual AIM listing and debt settlements.

Wellnex Life announces the resignation of joint CEO George Karafotias, with Zack Bozinovski stepping up as sole CEO. The company plans to repay a $705,000 director loan within 90 days.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Wellnex Life Limited has had its trading suspension lifted following its response to ASX queries related to a recent shareholder letter, reopening market access to its shares.

Wellnex Limited has withdrawn its recent announcement referencing a SP Angel research report containing forward-looking financial information, clarifying it does not endorse the projections.

The ASX has challenged Wellnex Life Limited over its recent shareholder announcement featuring forward-looking financial forecasts from SP Angel, prompting a mandated retraction due to disclosure shortcomings.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.